{Reference Type}: Journal Article
{Title}: Treatment Impact on the Long-Term Ocular Outcomes in Behçet's-Related Uveitis.
{Author}: Altıntaş H;Kardeş E;
{Journal}: Ocul Immunol Inflamm
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 20
{Factor}: 3.728
{DOI}: 10.1080/09273948.2024.2366906
{Abstract}: <B>UNASSIGNED: </B>To examine the demographic characteristics, findings and complication rates in patients with Behçet's uveitis (BU) and to investigate the effect of early biological therapy on the development of complications.<BR><B>UNASSIGNED: </B>Medical records of 94 patients with BU were retrospectively reviewed. Demographic data, ocular findings and complications at presentation, complications during follow-up, and treatments received during follow-up were analyzed. Patients who were followed for at least 24 months were divided into two groups according to the time of presentation as Group 1 (between 2009 and 2015) and Group 2 (between 2016 and 2021). Complications at the time of presentation and during follow-up, and treatments were compared.<BR><B>UNASSIGNED: </B>We enrolled 94 patients with a male-to-female ratio of 1.94 with a mean age of 30 ± 12 years. Median follow-up was 58.1(12-163) months. There were 35 patients (66 eyes) in Group 1 and 33 patients (61 eyes) in Group 2. At the time of presentation, end-stage disease, cataract, epiretinal membrane, and optic atrophy were significantly more common in Group 1 than in Group 2 (p < 0.05). A significantly higher proportion of eyes in Group 1 developed macular edema, cataract, epiretinal membrane, and macular atrophy during-follow-up (p < 0.05). Median time to initiation of biological treatment was 17.29 months in Group 1 and 3.33 months in Group 2 (p < 0.001). The overall complication rate was significantly lower in Group 2.<BR><B>UNASSIGNED: </B>Prognosis of BU is improved after the introduction of biological treatment. Early use of biological agents in BU is effective in decreasing sight-threatening ocular complications.